doi: 10.3389/fphar.2025.1591825 Received 11 March 2025 Accepted 28 August 2025 Published 08 October 2025 Volume 16 - 2025 Edited by Er Sheng Gong, Gannan Medical University, China Reviewed by Guillermo Federico Spitzmaul, National Scientific and Technical Research Council (CONICET), Argentina Leonardo Dionisio, National Scientific and Technical Research Council (CONICET), Argentina Updates Copyright 2025 Giannini, Soldi, Elli, Sagheddu, Castagnetti, Viciani, Salvini, Battistuzzi, Milazzo, Alibrandi and Sidoti
Ive already booked my next treatment, highly recommended
Our study identifies CD2AP as the gatekeeper of the podocyte TGF- response through its regulation of CatL expression and defines a molecular mechanism underlying proteinuric kidney disease
Long-term use is tolerable because the medication works with your body's natural regulatory pathways rather than against them
When I flagged it with my GP he said oh, thats just your B12 , nothing you can do about it What